Minneapolis, MN 9/5/17; Washington, DC 9/7/17—Scientific product firm Bio-Techne has acquired Trevigen for $11 million in cash. Bio-Techne was previously a distributor of Trevigen’s products. “The Trevigen products complement our current product portfolio and make it easier to reach customers interested in products to better understand cell behavior and genotoxic events on cells,” commented Bio-Techne President and CEO Charles R. Kummeth. “Having tools to study DNA damage and the apoptotic cell process is an important aspect of understanding drug action. As more drug testing is being conducted on physiologically more appropriate cell models, including 3D cell cultures, having membrane extracts products to support the robust growth of such cells, such as the Cultrex product line, makes these products an important addition to the Bio-Techne product line.” Trevigen was previously a Bio-Techne supplier. The acquisition is expected to be accretive to Bio-Techne’s fiscal 2018 adjusted EPS.

The acquisition expands Bio-Techne’s range of offerings for cell biology by adding more reagents and kits for applications, such as cancer research, which are also served by Bio-Techne, including its Tocris brand. Trevigen provides reagents and kits for cell research as well as products for physiologic cell culture. It also offers contract services through its Trevigen Cell Assays division.